Stock SCNI SCINAI IMMUNOTHERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Scinai Immunotherapeutics Ltd.

Equities

SCNI

US09073Q2049

Market Closed - Nasdaq
Other stock markets
 21:30:00 15/05/2024 BST 		5-day change 1st Jan Change
0.44 USD 0.00% Intraday chart for Scinai Immunotherapeutics Ltd. -2.20% -26.10%
05-06 Scinai Immunotherapeutics Plans 1-for-10 Reverse Stock Split to Avoid Possible Delisting MT
04-08 Exchange-Traded Funds, Equity Futures Gain Slightly Pre-Bell Monday as June Rate Cut Likelihood Falls MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update
PR
Scinai Immunotherapeutics : The Board has Approved a Ratio Change of the ADSs to Non-traded Ordinary Shares (equivalent to a reverse split) Designed to Regain Compliance - Form 6-K
PU
Scinai Immunotherapeutics CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services
AQ
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services
PR
Scinai leadership to attend BIO-Europe Spring 2024
PR
Scinai Immunotherapeutics to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024
AQ
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024
PR
Scinai Welcomes Liat Halpert as Head of Business Development and Sales
PR
Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Gorlich on Louis-Jeantet Prize
AQ
Scinai Immunotherapeutics CEO Issues Letter to Shareholders
PR
Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9
PR
Scinai Announces Promising Results in a Psoriatic Human Skin Model
PR
Study published in Antiviral Research supports promise of Scinai Immunotherapeutics coronavirus NanoAb as aerosolized prophylactic and therapeutic drug
AQ
Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug
PR
European Investment Bank extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031
AQ
European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031
PR
Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders Equity Rule
AQ
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
AQ
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
AQ
European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SCNI Stock
  4. News Scinai Immunotherapeutics Ltd.
  5. Press Releases